Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$2.66
-0.4%		$3.09
$2.56
▼
$6.44
$519.36M0.064.04 million shs3.16 million shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$16.01
+2.0%		$16.05
$10.90
▼
$19.25
$2.09B1.6824,351 shs682,529 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.40
+5.7%		$9.15
$6.00
▼
$11.22
$2.03B0.555.84 million shs5.12 million shs
Vericel Corporation stock logo
VCEL
Vericel
$40.74
+1.7%		$41.70
$28.95
▼
$49.32
$2.05B1.02539,621 shs646,999 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-10.10%-21.93%-14.15%-33.42%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-0.19%-4.45%-2.43%-3.33%+38.60%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-1.85%-3.87%-20.18%-28.44%+13.25%
Vericel Corporation stock logo
VCEL
Vericel
-2.48%-1.38%-0.35%-14.82%+18.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$2.66
-0.4%		$3.09
$2.56
▼
$6.44
$519.36M0.064.04 million shs3.16 million shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$16.01
+2.0%		$16.05
$10.90
▼
$19.25
$2.09B1.6824,351 shs682,529 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.40
+5.7%		$9.15
$6.00
▼
$11.22
$2.03B0.555.84 million shs5.12 million shs
Vericel Corporation stock logo
VCEL
Vericel
$40.74
+1.7%		$41.70
$28.95
▼
$49.32
$2.05B1.02539,621 shs646,999 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-10.10%-21.93%-14.15%-33.42%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-0.19%-4.45%-2.43%-3.33%+38.60%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-1.85%-3.87%-20.18%-28.44%+13.25%
Vericel Corporation stock logo
VCEL
Vericel
-2.48%-1.38%-0.35%-14.82%+18.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.70
Moderate Buy$14.33438.85% Upside
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.67
Moderate Buy$17.6710.35% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.50
Moderate Buy$20.50144.05% Upside
Vericel Corporation stock logo
VCEL
Vericel
2.67
Moderate Buy$58.4043.35% Upside

Current Analyst Ratings Breakdown

Latest ALT, AUPH, BCRX, and VCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $13.00
9/23/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/22/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Sell (D-)
9/21/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/10/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$13.00 ➝ $11.00
9/8/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$16.00
8/27/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/26/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/20/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Bloom Burton logo
Bloom Burton
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/12/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
8/7/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$15.00 ➝ $16.00
(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K12,935.58N/AN/A$1.99 per share1.34
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$283.05M7.53$1.03 per share15.48$4.41 per share3.63
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.45$1.31 per share6.42($0.57) per share-14.74
Vericel Corporation stock logo
VCEL
Vericel
$276.26M7.55$0.57 per share72.10$7.01 per share5.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$0.78N/AN/AN/AN/A-31.41%-26.96%11/5/2026 (Estimated)
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$287.20M$2.296.9914.82N/A100.84%26.11%19.89%11/3/2026 (Estimated)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A12.17N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$16.52M$0.4786.6848.50N/A7.91%6.91%5.02%11/5/2026 (Estimated)

Latest ALT, AUPH, BCRX, and VCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.22N/AN/AN/A$83.61 millionN/A
11/2/2026Q3 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.0903N/AN/AN/A$165.67 millionN/A
8/12/2026Q2 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.1355-$0.12+$0.0155-$0.12$0.00 millionN/A
8/6/2026Q2 2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.24$0.28+$0.04$0.28$80.45 million$58.57 million
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
7/30/2026Q2 2026
Vericel Corporation stock logo
VCEL
Vericel
-$0.0289$0.04+$0.0689$0.04$72.70 million$77.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.07
26.78
26.78
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.07
5.42
4.97
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.04
4.69

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
10.40%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Vericel Corporation stock logo
VCEL
Vericel
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
57194.52 million191.41 millionOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
128133.05 million119.21 millionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
435255.54 million245.83 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
39851.21 million47.32 millionOptionable

Recent News About These Companies

Vericel Corporation $VCEL Shares Sold by Congress Asset Management Co.
October 6 at 7:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vericel-corporation-vcel-shares-sold-by-congress-asset-management-co-2026-10-06/
Vericel (NASDAQ:VCEL) Stock Breaks Above Two Hundred Day Moving Average - Here's What Happened
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081617
Vericel (NASDAQ:VCEL) Shares Cross Above 200-Day Moving Average - Should You Sell?
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vericel-nasdaq-vcel-shares-cross-above-200-day-moving-average-should-you-sell-2026-10-03/
Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from Brokerages
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067786
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vericel-vcel-stock-looks-fully-220632180.html
Vericel Corporation (NASDAQ:VCEL) Stock Has Average Price Target of $58.40
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vericel-corporation-nasdaq-vcel-stock-has-average-price-target-of-5840-2026-09-25/
Bank of America Corp DE Invests $45.21 Million in Vericel Corporation $VCEL
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-invests-4521-million-in-vericel-corporation-vcel-2026-09-22/
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946828-vericel-corporation-vcel-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Vericel: MACI And Regenerative Knee Cartilage
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946289-vericel-maci-and-regenerative-knee-cartilage
Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vericel-corporation-vcel-shares-sold-by-wellington-management-group-llp-2026-09-12/
Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-scholtz-company-llc-buys-new-stake-in-vericel-corporation-vcel-2026-09-10/
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357642/34447/en/vericel-to-present-at-the-24th-annual-morgan-stanley-global-healthcare-conference-on-tuesday-september-15-2026.html
Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VCEL/latest-news/
Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares
August 1, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vcel-insider-buying-and-selling-2026-08-01/
Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928629-vericel-corporation-2026-q2-results-earnings-call-presentation
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927963-vericel-corporation-vcel-q2-2026-earnings-call-transcript
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964316/vericel-corporation-vcel-beats-q2-earnings-and-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2964316
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335958/34447/en/vericel-reports-second-quarter-2026-financial-results-raises-full-year-financial-guidance-and-announces-share-repurchase-program.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL) and Silence Therapeutics (SLN)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3542635/analysts-have-conflicting-sentiments-on-these-healthcare-companies-vericel-vcel-and-silence-therapeutics-sln/
Vericel Corp
July 24, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/vcel-vericel-corp/vitals
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328427/34447/en/vericel-to-report-second-quarter-2026-financial-results-on-july-30-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laptop displaying the Hims & Hers logo beside a gavel, pill bottle, and declining stock chart with the US Capitol.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
By Jessica Mitacek | September 24, 2026
Server hardware in a data center rack featuring a processor chip labeled with the Arm logo.
Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
By Jeffrey Neal Johnson | September 22, 2026
CrowdStrike logo, featuring a red falcon icon, displayed against a server data center corridor background.
The Ultimate Cyber Shield: CrowdStrike Rises Past $235
By Jeffrey Neal Johnson | September 16, 2026
Glass-walled office building lobby at sunset with a city skyline reflected in the exterior facade.
Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
By Chris Markoch | September 27, 2026
A quantum computer with layered gold and copper components sits open in a research laboratory setting.
3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
By Nathan Reiff | September 9, 2026
Altimmune stock logo

Altimmune NASDAQ:ALT

$2.66 -0.01 (-0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$2.67 +0.01 (+0.34%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.01 +0.32 (+2.04%)
Closing price 04:00 PM Eastern
Extended Trading
$15.98 -0.03 (-0.20%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.40 +0.45 (+5.66%)
Closing price 04:00 PM Eastern
Extended Trading
$8.39 -0.01 (-0.12%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Vericel stock logo

Vericel NASDAQ:VCEL

$40.74 +0.69 (+1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$40.74 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas